On April 15, 2026, Moleculin Biotech, Inc. held a Special Meeting, where stockholders approved the issuance of up to 6,367,956 shares related to certain warrants but rejected a proposal to change the company's name. 2,382,989 shares were represented at the meeting with a quorum established.